Liquidia Corporation
LQDA
$67.68
-1.43%
Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for pulmonary hypertension (PH), leveraging its proprietary PRINT particle engineering platform to create differentiated inhaled treprostinil products, including YUTREPIA and the investigational L606. As a niche player in the orphan drug space, Liquidia competes with larger players like United Therapeutics and Insmed, but its unique dry powder inhalation technology offers a potential edge in patient convenience and efficacy. The current investor narrative centers on YUTREPIA's commercial ramp and the upcoming regulatory and clinical milestones for L606, which are seen as key catalysts for growth, though competitive pressures and patent litigation remain overhangs.…
LQDA
Liquidia Corporation
$67.68
Related headlines
Investment Opinion: Should I buy LQDA Today?
Rating: Buy. Liquidia's explosive revenue growth, high gross margins, and attractive forward valuation make it a compelling investment. The analyst consensus is 'Buy' with an average target of $107.75, implying a 56.9% upside from the current price of $68.66.
Sign up to view all
LQDA 12-Month Price Forecast
The AI assessment is bullish with medium confidence, driven by strong fundamental performance and attractive valuation. However, the high debt and competitive risks temper confidence. If YUTREPIA sustains growth and L606 progresses, the stock could re-rate higher; conversely, any negative clinical or legal news would warrant a downgrade to neutral.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Liquidia Corporation's 12-month outlook, with a consensus price target around $107.75 and implied upside of +59.2% versus the current price.
Average Target
$107.75
0 analysts
Implied Upside
+59.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$90 - $130
Analyst target range
The target price range spans from $90.00 to $130.00, with the low target still representing a 31.1% upside, suggesting that even the most bearish analyst sees value. The high target of $130.00 implies a 89.3% upside, likely assuming successful L606 approval and continued YUTREPIA market share gains. The wide spread of $40 between low and high targets reflects uncertainty around regulatory outcomes and competitive dynamics, but the overall bullish sentiment is clear. With no recent downgrades and a consistent stream of 'Buy' ratings, the analyst community remains confident in Liquidia's growth trajectory.
Bulls vs Bears: LQDA Investment Factors
Liquidia presents a compelling bull case with explosive revenue growth, high margins, and a discounted forward valuation, but the bear case highlights intense competition, high leverage, and regulatory risks. Currently, the bull side has stronger evidence given the company's proven commercial execution and analyst confidence, but the most critical tension is whether YUTREPIA can sustain its growth trajectory against established competitors. If YUTREPIA continues to gain market share and L606 progresses successfully, the stock has significant upside; however, any competitive setback or legal adverse ruling could sharply reverse the thesis.
Bullish
- Explosive Revenue Growth: Q1 2026 revenue surged to $132.9M, a 41.6% YoY increase from $3.1M in Q1 2025, driven by YUTREPIA's commercial launch. This dramatic acceleration demonstrates strong market adoption and a successful transition from pre-commercial to commercial stage.
- Attractive Forward Valuation: With a forward PE of 12.15x and PEG of 0.83, the stock trades at a significant discount to the biotech industry average of 20-30x forward earnings. This suggests the market is pricing in conservative growth, offering potential upside if the company sustains its momentum.
- Strong Profitability Turnaround: Liquidia reported net income of $52.9M in Q1 2026, a stark contrast to the $38.4M loss in Q1 2025. The net margin of 39.8% and operating margin of 46.3% indicate efficient scaling and robust unit economics.
- High Gross Margin: Gross margin reached 90.9% in Q1 2026, reflecting the high-value nature of its proprietary PRINT technology and inhaled treprostinil products. This provides a strong foundation for profitability as revenue scales.
Bearish
- Intense Competitive Pressure: YUTREPIA faces fierce competition from United Therapeutics (UTHR) and Insmed (INSM), which have established products and larger sales forces. This could limit YUTREPIA's long-term market share growth and pricing power.
- High Debt-to-Equity Ratio: The debt-to-equity ratio of 4.42 indicates significant leverage, which increases financial risk. Interest expenses of $6.5M in Q1 2026 could pressure earnings if revenue growth slows or interest rates rise.
- Recent Price Volatility: The stock has pulled back 22.96% in the past month and is down 35.66% from its 52-week high of $93.61. This volatility, with a beta of 0.572, suggests sensitivity to company-specific news and market sentiment.
- Dependence on YUTREPIA: Revenue is heavily concentrated on YUTREPIA, with L606 still in development. Any setback in YUTREPIA's commercial ramp or regulatory issues could significantly impact the company's financials.
LQDA Technical Analysis
Liquidia's stock has been in a powerful uptrend over the past year, with a 1-year price change of +138.07%, dramatically outperforming the S&P 500's +18.65% over the same period. The current price of $68.66 sits at 65.4% of the 52-week range (low of $21.15, high of $93.61), indicating the stock has pulled back from its highs but remains well above its lows. This positioning suggests the market is still rewarding the company's growth story, but the recent correction from the peak may signal profit-taking or consolidation after a massive run.
Beta
0.54
0.54x market volatility
Max Drawdown
-35.7%
Largest decline past year
52-Week Range
$21-$94
Price range past year
Annual Return
+141.9%
Cumulative gain past year
| Period | LQDA Return | S&P 500 |
|---|---|---|
| 1m | -25.0% | -0.9% |
| 3m | +3.7% | +5.6% |
| 6m | +80.1% | +15.0% |
| 1y | +141.9% | +18.1% |
| ytd | +115.5% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LQDA Fundamental Analysis
Liquidia's revenue trajectory has been exceptional, with Q1 2026 revenue of $132.9 million, a 41.6% year-over-year increase, and a dramatic acceleration from the $3.1 million reported in Q1 2025. The company has transitioned from a pre-commercial stage to a commercial-stage company, with product revenue of $129.9 million in Q1 2026, driven by YUTREPIA's launch. This growth is a testament to the strong market adoption, but the sustainability of this pace is a key question given the competitive landscape.
Quarterly Revenue
$132865000.0B
2026-03
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
90.9%
Latest Quarter
Free Cash Flow
$41147000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LQDA Overvalued?
Given that Liquidia reported positive net income of $52.9 million in Q1 2026, the trailing PE ratio is -43.11 (due to prior losses), but the forward PE is 12.15, which is the most relevant metric. The forward PE of 12.15x is significantly lower than the industry average for biotech companies, which often trade at 20-30x forward earnings, suggesting the market is pricing in conservative growth expectations. The PEG ratio of 0.83 indicates that the stock is undervalued relative to its expected earnings growth, making it an attractive value proposition if the company can sustain its momentum.
PE
-43.1x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-68.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are notable. The debt-to-equity ratio of 4.42 indicates high leverage, with interest expenses of $6.5M in Q1 2026, which could strain cash flows if revenue growth decelerates. While the company turned profitable in Q1 2026 with a net income of $52.9M, this is a recent development, and the trailing PE of -43.11 reflects prior losses. Revenue concentration in YUTREPIA is a risk, as any commercial hiccup would directly impact the top line. The current ratio of 1.40 suggests adequate liquidity, but the high leverage amplifies financial risk.
FAQ
Key risks include intense competition from United Therapeutics and Insmed, which could limit YUTREPIA's market share. Financial risk is elevated due to a high debt-to-equity ratio of 4.42, which could strain cash flows if growth slows. Regulatory and legal risks are significant, with patent litigation and L606's approval process creating uncertainty. The stock is also volatile, with a beta of 0.572 and a recent drawdown of 35.66% from its high.
The 12-month forecast is bullish, with a base case target of $90-$110 (50% probability), a bull case of $100-$130 (30% probability), and a bear case of $50-$70 (20% probability). The most likely scenario is steady growth in YUTREPIA and progress in L606, leading to the stock reaching the analyst average target of $107.75. Key assumptions include sustained revenue growth and no major clinical or legal setbacks.
LQDA appears undervalued based on forward metrics, with a forward PE of 12.15x and PEG of 0.83, both below industry norms. The PS ratio of 18.75 is high, but this is typical for high-growth biotechs. The market is pricing in conservative growth, as evidenced by the low forward PE relative to the explosive revenue growth. If the company meets analyst estimates, the stock has significant upside potential.
LQDA is a good buy for investors with a high risk tolerance, given its explosive revenue growth and attractive forward valuation. The stock trades at a forward PE of 12.15x, well below the biotech average, and analysts see a 56.9% upside to the average target of $107.75. However, the stock is volatile, with a recent 22.96% pullback, and faces intense competition. A buy is justified if you believe YUTREPIA can sustain its growth and L606 will succeed; otherwise, the risks may outweigh the rewards.
LQDA is better suited for long-term investment, given its high growth potential and the time required for L606 to contribute. The stock is volatile, with a beta of 0.572 and a recent 22.96% monthly decline, making it risky for short-term trading. A minimum holding period of 3-5 years is recommended to allow the company to fully commercialize YUTREPIA and advance L606, potentially delivering substantial returns.